British Association for Cancer Research/'Association of Cancer Physicians/Society for Drug Research Joint Symposium on `Membrane Transport - Biology and Therapeutics' and BACR Members' Proffered Papers by unknown
Br. J. Cancer (1994), 69, 1184-1197
© Macmillan Press Ltd., 1994
MEETING REPORT
British Association for Cancer Research/Association of Cancer
Physicians/Society for Drug Research Joint Symposium on 'Membrane
Transport - Biology and Therapeutics' and BACR Members' Proffered
Papers
Held at Brian Drewe Lecture Theatre, Charing Cross & Westminister Medical School, The Reynolds Building, St Dunstan's Road,
Hammersmith, London W6 8RP, UK on 13/14 December 1993.
Abstracts of invited papers
The ABC superfamily of membrane transporters
C.F. Higgins
Imperial Cancer Research Fund, Institute of Molecular
Medicine, University of Oxford, John Radcliffe Hospital,
Oxford OX3 9DU, UK.
The human multidrug resistance P-glycoprotein is a member
of the ABC superfamily of membrane transporters. Over 50
members of this superfamily have now been identified, in
species including bacteria, yeasts, plants, insects and mam-
mals. These transporters are associated with a wide variety of
biological processes and, in man, several are associated with
clinical disorders. An overview of the structure and function
of ABC transporters will be presented.
The human multidrug resistance P-glycoprotein will be
discussed in detail, particularly its apparent relationship to
the cystic fibrosis gene product CFTR. P-glycoprotein con-
fers resistance of cancers to chemotherapy, pumping hydro-
phobic drugs from cells using the energy of ATP hydrolysis.
Recently, P-glycoprotein has also been shown to be associ-
ated with a chloride channel activity, although it is not
known whether P-glycoprotein is the channel or simply a
channel regulator. This chloride channel activity may reflect
a physiological role for this protein in regulating epithelial
cell volume. The possibility that P-glycoprotein is bifunc-
tional, associated with both active transport and channel
functions has general important implications for the distinc-
tion between channels and transporters. In particular, this
finding has implications for the development of drugs which
inhibit P-glycoprotein and reverse multidrug resistance. The
effect of inhibitors on the channel and transporter functions
associated with P-glycoprotein will be discussed.
Valverde, M.A. & others (1992). Nature, 355, 830-833.
Gill, D.R. & others (1992). Cell, 71, 23-32.
Trezise, A.E.O. & others (1992). EMBO J., 11, 4291-4303.
Higgins, C.F. (1992). Ann. Rev. Cell. Biol., 8, 67-113.
Murine P-glycoprotein: identification of drug binding and
phosphorylation sites
S.B. Horwitz
Department of Molecular Pharmacology, Albert Einstein
College of Medicine, Bronx, NY 10461, USA.
Drug resistance constitutes a major problem in the treatment
of human malignancies. Evidence is accumulating that multi-
drug resistance is one form of drug resistance that has a role
in human tumors. The multidrug resistance phenotype is
associated with the overproduction of P-glycoprotein, an
integral membrane phosphoprotein that acts as an energy-
dependent drug efflux pump with a broad specificity for
hydrophobic antitumor drugs. Each half of P-glycoprotein is
designated as a cassette that contains six putative transmem-
brane domains. Each cassette is followed by a nucleotide
binding domain and the two cassettes are joined by a linker
region. The use of '25I-iodoarylazidoprazosin and 3H-azi-
dopine, two photoaffinity probes that bind specifically to
p-glycoprotein, and immunological mapping methods have
located major photolabelled drug binding domains in each
cassette, immediately C-terminal to TM6 and TM12.
A combination of cyanogen bromide digestion and
immunoblot analysis has been usd to domain map the phos-
phorylation sites in p-glycoprotein. The majority of phos-
phorylation occurs within a single cyanogen bromide frag-
ment (amino acids 627-682) that encompasses the majority
of the linker region. Our studies indicate that in vitro protein
kinase C and protein kinase A phosphorylation occurs at
serines 669 and 681, respectively. The effects of phosphoryla-
tion on p-glycoprotein function are being evaluated.
Multidrug resistance, drug accumulation and intra-celHular
drug distribution
H.J. Broxterman, G.J. Schuurhuis, C.H.M. Versantvoort,
H.M. Pinedo & J. Lankelma
Department ofMedical Oncology, Free University Hospital, de
Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Multidrug resistance refers to the type of resistance to cyto-
static drugs with different chemical structures and different
cellular targets caused by mechanisms that result in a
decreased concentration of drugs at the target sites. ATP
dependent drug transporters have been identified recently in
mammalian cells, including human cancer cells. Upregulation
of such drug transporter activity frequently occurs upon in
vitro selection of tumor cell lines with cytostatic drugs.
I will discuss data from our laboratory on daunorubicin
(DNR) transport by three drug transporters: P-glycoprotein
(Pgp), 'GLC4/ADR' type (small cell lung cancer) and 'SW-
1573/2R120' type (non-small cell lung cancer). Evidence for
active drug transport in these systems is: (a) DNR (and
VP-16) efflux is ATP-dependent; (b) DNR efflux is against a
concentration gradient; (c) upon permeabilization of the
plasma membrane with low digitonin concentrations there is
DNR net influx, showing that the cytoplasmic drug concent-
ration is kept below the extracellular concentration. Further-
more, differences in passive drug permeation (passive
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permeation coefficient), intracellular pH or DNA content
could not explain the DNR accumulation defects.
Additional evidence for presence of a drug transporter is
the saturability of the active DNR transport; assuming sim-
ple Michaelis-Menten kinetics and no preference for neutral
DNR transport by the pump we could calculate an apparent
Km of 1.5tLM for DNR transport by Pgp as well as the
'GLC4/ADR' transporter.
A further characteristic of drug transporters is the pos-
sibility to inhibit DNR transport by agents that compete for
the drug interaction with the transporter. An example will be
shown of the competitive interaction of the isoflavonoid
genistein with the 'GLC4/ADR' transporter.
Another characteristic of many MDR cells is the relatively
more decreased accumulation ofanthracyclines in the nucleus
(N), compared to the cytoplasm (C), leading to e.g. a lower
doxorubicin fluorescence N/C ratio in MDR compared to
sensitive cells. A decrease in drug accumulation plus altered
drug distribution in many cases may explain the resistance in
(Pgp)/MDR cells. Also this method can be used to screen for
an MDR phenotype in individual cells, e.g. in human acute
myeloid leukemic blasts, using fluorescence microscopy.
We conclude that future efforts to identify functional drug
transporters, together with gene-specific (MDRI, MRP ...?)
analysis of tumors would lead to a better insight of cellular
MDR and possibilities to reverse specifically these types of
resistance.
Clinical trials of modulation of multidrug resistance
B.I. Sikic
Oncology Division, Stanford University School of Medicine,
Stanford, California 94305-5306, USA.
Multidrug resistance (MDR), mediated by P-glycoprotein (P-
gp) and encoded by the mdrl gene, is one of the best
understood mechanisms of resistance to anticancer drugs. A
growing body of evidence indicates that expression of mdrl
contributes to clinical resistance to chemotherapy. P-gp in
normal tissues may be important in the excretion of MDR-
related anticancer agents as well as many other drugs.
Several clinical trials have attempted to modulate MDR by
co-administration of non-cytotoxic inhibitors of P-gp such as
verapamil or cyclosporine. Interpretation of such trials is
complicated by several factors: (1) Adequate concentrations
of modulating agents may not be achievable because of
toxicities (e.g. hypotension and heart block with verapamil;
nephrotoxicity of cyclosporine). (2) The pharmacokinetic
consequences of the drug interactions which are produced
often have not been well characterized (drug levels of both
modulator and cytotoxins). We have shown that high dose
cyclosporine inhibits the disposition of etoposide, doxo-
rubicin, and taxol. Dose modification factors of 2-fold have
been observed, requiring dose reductions of the cytotoxic
agents. (3) The modulating drug may not be bioavailable due
to binding to cellular or serum proteins (e.g. amiodarone). (4)
Proper controls should be included (proven clinical resistance
to prior therapy, or a randomized control group without the
modulator). (5) mdrl expression by tumor cells is an impor-
tant factor in assessing response to modulation in Phase 2
and 3 trials. (6) Even if the tumor expresses mdrl, redundant
mechanisms of resistance may be present in tumor cells. The
prognostic significance of tumor mdrl expression and anec-
dotal observations of partial remissions with modulation of
MDR have led to sustained interest in this area. Several
promising new modulators are being developed. Among
these, the cyclosporin D analogue PSC 833 is completing
Phase I trials. The keys to successful clinical investigations of
this approach are at hand: potent new inhibitors are being
tested, molecular diagnostic tools for identification of P-gp
and other resistance mechanisms are available, and the
clinical pharmacology of these complex drug interactions is
being defined.
Yahanda, A.M. & others (1992). J. Clin. Oncol., 10, 1624-1634.
Lum, B.L. & others (1992). J. Clin. Oncol., 10, 1635-1642.
Sikic, B.I. (1993). J. Clin. Oncol., 11, 1629-1635.
The Gordon Hamilton-Fairley Memorial Lecture
Multidrug resistance: friend or foe?
M.M. Gottesman
Laboratory ofCell Biology, National Cancer Institute, National
Institutes of Health, Bethesda, Maryland 20892, USA.
The cloning of a cDNA for the human MDR1 gene, and the
demonstration that expression vectors encoding the multi-
drug transporter (P-glycoprotein) could confer multidrug
resistance on sensitive cells, made possible the use of these
vectors for human gene therapy. Two possible approaches
can be considered: (1) use of MDR1 expression vectors to
confer multidrug resistance on tissues normally susceptible to
the toxic effects of chemotherapy, especially bone marrow;
and (2) use of MDR1 expression vectors which also encode
otherwise non-selectable genes so that selection for multidrug
resistance results in expression of these non-selectable
markers. The advantages of using the MDR1 cDNA for such
studies include the broad spectrum of drug resistance encod-
ed by this cDNA, the surface localization of P-glycoprotein
allowing for easy detection and sorting, and the ability to
create 'designer' MDR1 vectors with substrate and inhibitor
specificities which are distinct from the endogenous MDR1
gene. Using retroviral vectors, the human MDR1 cDNA has
been successfully transferred into mouse bone marrow, where
it confers resistance to taxol and daunorubicin in vivo. Three
clinical trials in which a human MDR1 cDNA will be trans-
duced into bone marrow of patients undergoing autologous
bone marrow transplantation for brain tumors and cancers
of the ovary and breast have recently been approved by the
Recombinant Advisory Committee in the US. We are also
developing vectors which utilize the MDR1 gene to select for
a second gene; such vectors include the second gene in a
bicistronic message in which translation initiation is facili-
tated using an encephalomyocarditis internal ribosome entry
site (IRES), or encode chimeric proteins in which P-glyco-
protein is covalently linked to a non-selectable gene under
conditions in which the chimera is bifunctional.
Non-P-glycoprotein-mediated multidrug resistance
P.R. Twentyman & M.A. Barrand
MRC Clinical Oncology and Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
In many multidrug resistant (MDR) cell lines, decreased
cellular drug accumulation is accompanied by overexpression
of the putative drug efflux pump molecule, P-glycoprotein
(Pgp), at the plasma membrane. A number of cell lines have,
however, been reported which, whilst having a similar spec-
trum of drug resistance and showing a drug accumulation
deficit, do not overexpress Pgp or the encoding MDR1 gene.
Such cells may show striking changes in intracellular distri-
bution of doxorubicin or daunorubicin from that seen in
parental cells. Resistance modifiers such as verapamil or
cyclosporin A are relatively ineffective in reversing drug resis-
tance in cells with the non-Pgp MDR phenotype. By screen-
ing with antisera raised to synthetic peptides from the1186 JOINT WINTER MEETING REPORT
deduced amino acid sequence of Pgp, Marquardt et al.
(Cancer Res., 50, 1426, 1990) were able to detect a 190k
protein overexpressed in the non-Pgp MDR human leukae-
mic cell line HL60/Adr. The antiserum ASP14 which detected
this protein also recognised a protein of similar size in our
non-Pgp human large cell lung carcinoma MDR line COR-
L23/R. Furthermore, an analogous antiserum, CRA-1, raised
in our laboratory has shown the protein to be present in
other lung cancer cell lines with non-Pgp MDR phenotypes.
Recently, the sequence of a novel transporter gene (MRP)
has been identified from a doxorubicin-selected human small
cell lung cancer MDR cell line (H69AR) which does not
overexpress Pgp (Cole et al., Science, 258, 1650, 1992). The
MRP protein contains a seven amino acid sequence that is
identical to a portion of the peptide used to raise antisera
ASP14 and CRA-1. We have now shown that (a) the amount
of 190 k protein correlates well with degree of resistance in a
number of resistant and revertant cell lines; (b) the amount
of MRP mRNA as determined by RT-PCR correlates closely
with that of the 190 k protein; (c) non-Pgp MDR cell lines
containing 190 k protein show evidence of gene amplification
on chromosome 16, the location of the MRP gene. We
therefore conclude that the 190 k protein represents the pro-
duct of the MRP gene. We have investigated a number of
agents as possible 'resistance-modifiers' for this type of
MDR. These include vacuolar ATP inhibitors bafilomycin A
and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole, the fungal anti-
biotic brefeldin A, and the ionophore, nigericin. Each of
these agents will bring about partial restoration of drug
accumulation in COR-L23/R cells, but only at doses which
are close to the toxic range for the modifier alone. The MRP
gene has been shown to be expressed at high levels in blood
mononuclear cells. This complicates interpretation of expres-
sion determined in tissue homogenates which have a signifi-
cant mononuclear cell infiltration. Furthermore, the fluores-
cent dye, rhodamine 123, is rapidly effluxed from MDR cells
which are Pgp negative but which overexpress MRP. This
potentially complicates the use of rhodamine 123 as a probe
for Pgp function in human haemopoietic cells of different
lineages.
Folate transport systems
J.H. Schornagel, G.R. Westerhof, I. Kathmann & G. Jansen
Department of Internal Medicine, The Netherlands Cancer
Institute, 1066 CX Amsterdam, The Netherlands.
For the cellular uptake of folates two structurally distinct
membrane transport routes have been identified; a carrier-
mediated system, designated hereafter as the reduced folate
carrier (RFC) and a receptor-mediated system, designated as
membrane-associated folate receptor (MFR). RFC and MFR
differ considerably in their mechanism of uptake (channel
function vs receptor-mediated endocytosis/potocytosis), affin-
ities for natural reduced folate cofactors (CuM range vs nM
range) and rate of membrane translocation (under Vmix con-
ditions the turnover number of molecules per minute per
transporter molecule is 3-4 orders of magnitude faster for
RFC than for MFR). The RFC and MFR also play a major
role in the internalization of cytotoxic antifolates into
tumour cells. The RFC system is an efficient transport route
for the classical antifolate methotrexate (MTX) as well as for
some of the newer antifolates which are currently being
evaluated in phase I/II clinical trials. The role of MFR in the
clinical pharmacology of antifolates is as yet unclear. The
affinity of MFR is approximately 100-fold lower for MTX
than for folic acid, but MFR may be a preferred route for
uptake of novel antifols for which it has a high affinity, such
as some new folate-based inhibitors of thymidylate synthase
(TS) and glycinamide ribonucleotide transformylase
(GARTF-ase). The mechanism of this receptor-mediated
uptake by MFR is not well understood. Interestingly, some
tumour types (e.g. ovarian cancer) are known to express high
amounts of MFR, which could be exploited therapeutically.
Several mechanistic as well as pharmacological aspects of
both transport systems will be discussed.
Transport of platinum-based cytotoxics
L.R. Kelland
Drug Development Section, The Institute of Cancer Research,
Sutton, Surrey SM2 SNG, UK.
The platinum (Pt)-based anticancer drugs cisplatin (CDDP)
and carboplatin (CBDCA) have made a major impact on the
treatment of some cancers, especially testicular and ovarian
tumours. However, these tumours commonly acquire resis-
tance to CDDP/CBDCA while other tumour types (e.g., non
small cell lung and colorectal cancer) are intrinsically resis-
tant. Over recent years is has become apparent that resis-
tance to CDDP is often multifactorial; involving one or more
of reduced drug accumulation, increased intracellular detoxi-
fication through elevations in glutathione and/or metallo-
thioneins, and enhanced removal of Pt-DNA adducts.
The majority of in vitro-derived cell lines with acquired
CDDP resistance exhibit some reduction (typically around
50%) in Pt accumulation compared to the parent line. Des-
pite this finding however, it remains largely unclear how
CDDP enters cells and, moreover, the mechanisms underly-
ing the decreased accumulation observed in many resistant
tumours. In contrast to the membrane p-170 glycoprotein
mediated multidrug resistance phenotype (due to enhanced
drug efflux) the membrane component of CDDP resistance
occurs mainly through reduced Pt influx.
CDDP accumulation into cells is consistent with mechan-
isms involving both passive diffusion and active carrier-
mediated transport. CDDP accumulation is proportional to
drug concentration, is not inhibited by structural analogues
and is not saturable even up to mm concentrations. On the
other hand, accumulation may be modulated by a variety of
agents (decreased by aldehydes or the Na+/K+-ATPase
inhibitor ouabain and increased by amphotericin, dipyrid-
amole and effectors of protein kinase C and protein kinase A
intracellular signal transduction pathways). Furthermore,
there have been recent reports of antibodies raised against
CDDP-resistant cells which detect membrane-linked proteins
associated with CDDP accumulation (e.g., Kawai et al.,
1990, J. Biol. Chem., 265, 13137). Recently it has been pro-
posed that at least some component of CDDP accumulation
occurs through a gated ion channel (Gately & Howell, 1993,
Br. J. Cancer, 67, 1171).
CDDP resistance due to reduced drug accumulation may
also be circumvented by novel Pt-based complexes. Studies
using the more lipophilic Pt drug JM216 [bis-acetato-
ammine-dichloro-cyclohexylamine platinum (IV)] (currently
in phase I clinical trial as the first orally administrable Pt
drug) have shown circumvention of CDDP-resistance in
accumulation defective human ovarian carcinoma 41McisR
cells (Kelland et al., 1992, Cancer Res., 52, 3857).
Topoisomerases II - other mechanisms of resistance to drugs
and cell death
A.L. Harris, I.D. Hickson, G. Tortora, J. Jenkins, A. Fry,
S. Davies & S. Houlbrook
ICRF Molecular Oncology Laboratories, Institute of Molecu-
lar Medicine, John Radcliffe Hospital, Headington, Oxon.,
UK.
Topoisomerase II is a key target for many drugs transported
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rubicin, Doxorubicin, Daunorubicin, Ellipticine, Mitoxant-
rone, C1941, Aclacinomycin, ICRF154 all interact with
topoisomerase II. Genetic and epigenetic mechanisms of
resistance to these drugs involve topoisomerase II genes and
their regulation. There are two forms of topoisomerase II, a
and b with different chromosome localisations, cell cycle
regulation and subcellular localisation. During development
of drug resistance either or both may be down regulated in
expression. Lower levels are associated with resistance. Phos-
phorylation is essential for their activity and we have demon-
strated several kinases that can activate the enzymes includ-
ing protein kinases C, protein kinase A and casein kinase 2.
Mutants with abnormal sensitivity to topoisomerase II inhib-
itors have been isolated which are also hypersensitive to
Cyclic AMP analogues. There is no change in topoisomerase
II activity in these mutants or in its expression. Transfection
of a regulatory sub unit of protein kinase A - Rla alters the
sensitivity to topo II inhibitors without changing enzyme
expression. This suggests that PKA is involved in down-
stream events such as apoptosis. Rla expression is commonly
elevated in cancer, it may be related to the selective activity
of these anti-tumour agents. Thus changes in topoisomerases
and intracellular signalling pathways may be important
mechanisms of drug resistance and differential sensitivity of
tumour cells. Design of drugs with selective activity against
different forms may be of therapeutic value.
Abstracts of members' proffered
papers
1.1 Phase I Clinical trial of a new anti oestrogen idoxfene in
advanced breast cancer
M. Quigley2, B. Haynes3, M. Dowsett4, M. Jarman', I.W.
Hanham2 & C. Coombes'
Departments of 'Medical Oncology and 'Radiotherapy, Char-
ing Cross Hospital, 'The Institute of Cancer Research, Sutton
and 4Department of Academic Biochemistry, Royal Marsden
Hospital, UK.
Tamoxifen is at present the antioestrogen of choice in breast
cancer but it has relatively low affinity for the oestrogen
receptor (ER) and is a partial agonist. Idoxifene (Pyrrolidino-
Iodo-Tamoxifen). It belongs to the Triphenylethylene group
of anti-estrogens. Idoxifene appears to have reduced agonist
activity, improved ER binding and a greater anti proliferative
activity in vitro and in vivo. We conducted a phase I clinical
trial using oral Idoxifene to assess its toxicity, pharmaco-
kinetics, endocrine profile and tumour response. Twenty
heavily pre-treated post menopausal women with histologic-
ally proven breast cancer were entered into the trial between
July 1992 and January 1993. Treatment consisted of oral
Idoxifene at four dose levels, 10 mg, 20 mg, 40 mg and 60 mg
and five patients had each dose level. Patients received a
single oral dose of Idoxifene followed a week later by a daily
oral dose for 1 week. Fourteen patients continued for longer
periods (5-48 weeks). Two patients are still on Idoxifene.
Blood samples were taken for pharmacokinetics, biochemis-
try, haematology, serum lipids, oestradiol, FSH, LH and
SHBG. Idoxifene was well tolerated with no serious drug-
related adverse events. Six patients complained of hot flushes,
four of nausea and three ofvomiting (all CTC grade I). Four
patients complained of tiredness.
Idoxifene showed linear pharmacokinetics and plasma con-
centrations and AUC values of Idoxifene (single dose) were
very similar to Tamoxifen. A more accurate assessment of
the terminal half-life of Idoxifene was available in the four
patients who discontinued therapy after 56-240 days of
treatment. A mean value of 29.1 ± 4.2 days was obtained in
these patients, which was four times longer than that cal-
culated in the single phase of the study.
Five patients were excluded from the statistical analysis on
the endocrine data because they had certain characteristics of
being pre menopausal. Falls were observed for LH & FSH. It
woud appear that the drug does have agonist effects on
gonadotrophins. There was no difference between the high
and low doses in respect to the agonist effects but the
numbers were small. Response data is available on 12
patients.
There has been one definite response. A phase II trial is
now in progress.
1.2 The in vitro drug sensitivity of 8-chloro-cAMP in
leukaemia and lymphoma
A.G. Bosanquet', A.R. Burlton', P.B. Bell', D. Talbot2 &
A.L. Harris2
'Bath Cancer Research Unit, Royal United Hospital, Bath
BAJ 3NG; and 'ICRF Clinical Oncology Unit, Churchill Hos-
pital, Oxford OX3 7LJ, UK.
8-Chloro-cAMP (8-Cl-cAMP) is a cAMP analogue with a
novel antitumour action [Cho-Chung, Y.S. et al. 1991, Phar-
mac. Ther., 50, 1]. Whilst it is being investigated in a Phase I
clinical trial in solid tumours, we have tested its in vitro drug
sensitivity in leukaemia and lymphoma using the Differential
Staining Cytotoxicity (DiSC) assay [Bosanquet, A.G. (1991,
Lancet, 337, 711]. Fresh isolated human tumour cells were
incubated with 1.5-380,ug/ml 8-Cl-cAMP for the 4 days of
the assay to identify an LC9,. Two of the three acute myeloid
leukaemia (AML) specimens were sensitive in vitro (LC90s =
1.5, 12ytg/ml) compared with the median of all specimens
tested of 38 Ag/ml. This confirms observations that AML cell
lines are sensitive to this drug [Cho-Chung]. Non-Hodgkin's
lymphoma and chronic lymphocytic leukaemia specimens
showed less sensitivity with LCgos of 24->380jig/ml. Two
specimens that contained only normal cells at the end of the
incubation period were very resistant to the drug (LC90s>>
380jig/ml) suggesting a good in vitro therapeutic index. We
correlated these results with the LCgos of the similar drugs
fludarabine (2-fluoro-ara-AMP, Fl) and cladribine (2-Cl-
deoxyadenosine, CDA). Whilst Fl and CDA were strongly
cross resistant (n = 30, r2= 0.72, P = 5 x 10-9) there was
little cross resistance of these drugs to 8-Cl-cAMP (8-Cl-
cAMP vs. Fl, n = 30, r2 = 0.07, P = 0.16; 8-Cl-cAMP vs.
CDA, n = 31, r2= 0.19, P=0.015). These results suggest a
role for 8-Cl-cAMP in leukaemias and lymphoma and especi-
ally against AML.
1.3 Antitumour activity in vitro of an inhibitor of Golgi
assembly, brefeldin A
J.A. Plumb, A. Wise, M. O'Prey', L. Coggins' & P. Workman
CRC Department ofMedical Oncology, University ofGlasgow
and 'Beatson Institute, Garscube Estate, Glasgow G61 IBD,
UK.
Brefeldin A, a fatty acid derivative of fungal origin, inhibits
movement of membrane proteins from the endoplasmic retic-
ulum to the Golgi and hence causes disassembly of the Golgi
apparatus (Lippincott-Schwartz et al., Cell, 60, 821, 1990).
We have investigated the potential antitumour activity of
brefeldin A in vitro in a number of human tumour cell lines.
The Golgi complex was visualised by the use of confocal
microscopy and a fluorescent lipid probe, BODIPY ceramide,
which specifically associates with Golgi membranes in living
cells. Cytotoxicity (ID50 0.7-5.3 JM) was observed after
exposure to Brefeldin A for only 1 h. Furthermore, the ID,,
concentration was close that required for disassembly of the
Golgi apparatus. PtKl cells, derived from the kangaroo rat
kidney, are known to be resistant to the effects ofbrefeldin A
on the Golgi apparatus (Ktistakis et al., J. Cell Biol., 113,1188 JOINT WINTER MEETING REPORT
1009, 1991). We have shown that these cells are also resistant
to the cytotoxic effects of Brefeldin A such that no cell kill
was observed at the limit of solubility of Brefeldin A (100jLg/
ml, 357 liM).
It has been suggested that accumulation of cytotoxic drugs
in intracellular compartments and increased vesicular traffick-
ing may play a role in drug resistance. Treatment of multi-
drug-resistant breast (MCF7Adr) and ovarian (2780AD) cell
lines with brefeldin A at concentrations shown to disrupt the
Golgi apparatus had no effect on sensitivity to doxorubicin.
This suggests that this is not an important mechanism in
these cell lines even though we were able to demonstrate
co-localisation of doxorubicin and BODIPY ceramide in the
breast cell line.
These results suggest that brefeldin A has potent anti-
tumour activity and that the mechanism of action may be
related to effects on intracellular membrane trafficking.
1.4 Effect of essential fatty acids (N-6) on the growth of
human colonic cancer cells
G.S. Lindsay & H.M. Wallace
Departments of Medicine and Therapeutics and Biomedical
Sciences, University of Aberdeen AB9 2ZD, UK.
It has been suggested that the essential fatty acids (EFAs) of
the n-6 series promote the growth of tumour cells while the
EFAs of the n-3 series inhibit the growth of these cells.
However there is some controversy as to whether all
members of the n-6 series promote the growth of tumour
cells. The aim of this study was to determine the effects of
two EFAs, linoleic (Cl8:2 n-6; LA) and y-linolenic (C18:3
n-6; GLA) acids, on the growth of human colonic carcinoma
cells (HT115) in culture. Cells were grown in monolayer
culture under standard conditions in medium supplemented
with 10% (v/v) horse serum. Cells were exposed to the EFAs
for 96 h and cell growth analysed by changes in cell number,
protein content and DNA synthesis. Polyamine content was
also measured as an index of the rate of cell growth. LA
increased both protein content and cell number at concentra-
tions of 5 and 20 g/ml with little effect on the cell viability. In
contrast, GLA at the same concentrations had little effect on
protein content by inhibited cell division, as measured by
change in cell number, and viability (Table 1).
Table I Effect of LA and GLA on HT115 cell growth (*P<0.05)
Protein content Cell number Viability
Treatment (mg/plate) ( X 10-6) (%)
LA GLA LA GLA LA GLA
Ethanol 0.63 0.64 1.63 1.20 86 81
5 g/ml 0.81* 0.58 1.69 0.52 84 72
20 g/ml 0.89* 0.53* 2.01 0.46 83 68
LA had little effect on polyamine content while GLA decreased
spermine. Effects on DNA synthesis paralleled those on cell
number. Clearly only LA has a stimulatory effect on the growth
ofthese tumourcellswhile GLA isinhibitory as are the EFAs of
the n-3 series.
1.5 Induction ofapoptosis by withdrawal of serum in a pl85neu
transformed human mammary epithelial cell line
R.A. Harris', M. Page' & M.J. O'Hare2
'Wellcome Research Laboratories, Beckenham, Kent BR3 3BS;
and2ICR, Haddow Laboratories, Sutton SH2 SNS, UK.
Apoptosis is a form ofprogrammed cell death characterised by
morphological alterations, which include chromatin condensa-
tion, blebbing of the plasma and nuclear membranes, the
shrinkage of cell volume, and is often associated with the
cleavage of DNA into nucleosomal unit lengths. It has been
suggested that in developing malignancies, the rate of tumour
growth is linked to the relative rates of cell proliferation and
apoptosis. Many anti-tumour agents have been reported to act
by inducing apoptosis, both in vivo and in vitro.
A conditionally immortalised human mammary luminal
epithelial cell line, HB4A, derived by transfection of the
tSA58.U19 large T-antigen, was transformed by introduction of
the mutant neu gene. After serum-withdrawal the parental
HB4A line growth arrested, whereas the neu transformed
derivative, N4.1, displayed all the characteristics of apoptosis.
The alterations ofcellular morphology produced by the pheno-
menonwereobservedduringtime-lapse photography, while the
condensation of chromatin was confirmed by both DNA
histogram analyses and electron microscopy. The nucleosomal
cleavage of DNA is being examined by agarose gel electro-
phoresis. Apoptosis in N4.1 was abrogated by the addition of
glucocorticoids, but not by other steroids.
Theseobservationsprovideamodelforthestudyofapoptosis
in human mammary luminal epithelial cells. If apoptosis is a
regulated pathway in human breast tumour cells, it could be
manipulated for potential therapeutic use. Thus, it may ulti-
mately be possible to induce apoptosis specifically in tumour
cells.
1.6 Prediction of accumulation of 1311-meta-iodobenzylguani-
dine in neuroblastoma cell lines by means ofreverse transcription
and polymerase chain reaction
R.J. Mairs', A. Livingstone' & M.N. Gaze2
'Department of Radiation Oncology, University of Glasgow,
Garscube Estate, Glasgow G61 IBD,2TheMeyerstein Institute of
Clinical Oncology, The Middlesex Hospital, Mortimer Street,
London WIN 8AA, UK.
'31I-meta-iodobenzylguanidine (mIBG) is concentrated in sym-
pathetic neurones, adrenal medullary cells and neural crest-
derived tumours by an active process which is mediated by the
noradrenalinetransporter. Targetedradiotherapyofneuroblas-
toma using '3I-mIBG currently provides one of the best
examples of selective anti-cancer therapy using radionuclides.
In order to identify those patients for whom 3'I-mIBG
therapy will be appropriate, and to estimate dosimetry and
response to this form of treatment, a pre-therapy "31I-mIBG
tracer study is usually carried out. This procedure, however, is
only useful in patients with residual macroscopic tumour.
In the pursuance of a cost-effective alternative to time-
consumingmIBGscintigraphicproceduresofdubiousprecision
and of a procedure which should be applicable to all patients
irrespective of disease status, we evaluated the potential of
reverse transcription followed by the polymerase chain reaction
(RT-PCR) to predict mIBG uptake. The expression of the
noradrenaline transporter gene was compared with that ofthe
28S rRNA gene in six human neuroblastoma cell lines and in
three non-neural crest-derived cell lines. Transcription of the
noradrenaline transporter gene was observed in five out of six
neuroblastoma cell lines but in none of the control cells.
The RT-PCR procedure was specific (target mRNA
sequences wereabsentincontrolcells, and the PCRproductand
its restriction endonuclease-derived fragments were of the
predicted sizes), reproducible (coefficient ofvariation >13.2%)
and sensitive (detection limit <50 ng of total RNA). A highly
significant correlation was established (P<0.01) between gene
expression and active cellular accumulation of mIGB. It is
suggested that semi-quantitative evaluation of noradrenaline
transporter gene transcripts may be predictive ofmIBG uptake
by tumours in vivo.JOINT WINTER MEETING REPORT 1189
1.7 Formation of DNA triplexes between oligonucleotides and
N-myc
J.A. O'Donoghue', R.J. Mairs' & T. Brown'
'Department of Radiation Oncology, University of Glasgow
and 2Department of Chemistry, University of Edinburgh, UK.
Amplification of N-myc has been reported in several tumour
types including neuroblastoma, where it is associated with a
poor clinical prognosis. It may therefore be a good candidate
for targeted radionuclide therapy using triplex forming
oligonucleotides as targeting vectors. Oligonucleotides were
designed to form DNA triplexes with a 25 bp homopurine-
homopyrimidine region at the 5' end of the N-myc gene as
shown in the table.
Table Sequences of the target duplex and oligonucleotides
N-myc Target Duplex
5'-GGTAAAGCCGC TTTCCTCTCCTTTCTCCCTCCCCCI1TGTC
TGCGCCACA-3'
3'- TITCGGCG AAAGGAGAGGAAAGAGGGAGGGGGAACAGA
CGCGGTGTCGG-5'
Targeting Oligonucleotides
Ntl 5'-AGGGGGAGGGAGAAAGGAGAGGAAA-3'
Nt2 5'-AAAGGAGAGGAAAGAGGGAGGGGGA-3'
Nt3 5'-TGGGGGTGGGTGTTTGGTGTGGTTT-3'
Nt4 5'-TTTGGTGTGGTTTGTGGGTGGGGGT-3'
The boxed regions indicate the anticipated sites oftriplex formation.
In an assay oftriplex formation 5'-end labelled oligonucleotides
wereincubated withvarying concentrations oftheN-myctarget
duplex in 20 mM Tris-Cl (pH 7.2) 10 mM MgCl2 10% sucrose.
Forthetriplex inhibitionassaytheincubationbufferwas 20 mM
Tris-Cl (pH 7.2) 2 mM EDTA 10% sucrose. Polyacrylamide gel
electrophoresis was performed for 3 h at 500 V at room
temperature.
Subsequently, 3'-end labelled N-myc target duplex was
incubated with varying concentrations of the targeting
oligonucleotides. Electrophoresis was performed for triplex
forming and triplex inhibition assays as above. We now have
data consistent with DNA triplex formation between the
targeting oligonucleotides Nt2 and Nt4 and the N-myc target
duplex. Neitheroftheother twoN-myctargetingoligos Ntl and
Nt3 forms triplexes. The formation oftriplexes between N-myc
and Nt2 or Nt4 is inhibitable by incubation and electrophoresis
in the presence of 2 mM EDTA.
Preliminary data suggest that Nt4 forms a stronger associa-
tion than Nt2 with N-myc.
2.1 Oncogene status of bladder tumours: the value of multi-
parametric flow cytometry
B.K. Shenton, K. Mellon, S. Wilkinson, I. Brotherick, B.
Angus, C.W.V. Horne, T.W. Lennard & D.E. Neal
Department of Surgery, Medical School, University of New-
castle, Newcastle NE2 4HH, UK.
Mutations and over-expression of the p53 gene have been
reported to be one of the most common genetic alterations in
humanmalignancy. The determination ofsuch abnormalities is
usually by immunoprecipitation, sequencing or by immuno-
cytochemistry. In the present study we have examined tumour
cells from frozen bladder tumours of 14 patients using flow
cytometry. The panel of FITC conjugated antibodies used
included four to different p53 epitopes, and one to c-erbB2. We
employed a permeabilisation process to the cells using saponin
which allowed the simultaneous assessment of surface and
intercellular components. Titration of the conjugated anti-
bodies was performed to determine their optimum concentra-
tions.
The presence of aneuploidy was highly associated with
p53-240 (P = 0.007), p53-DO7 (P = 0.035) and c-erbB-2
(P = 0.0023) but not with expression ofp53-CM1 or p53-1801.
Similar results were seen in 12 tumour lines tested where the
tumours could be separated into different groups based upon
theirp53 epitope expression. High correlations were also found
between the presence ofc-erbB2 and bothp53-DO7 (P = 0.035)
and p-53-240 (P = 0.008) expression on the tumour cells.
These studies indicate that multiparameter flow cytometry
may be a valuable investigative tool in the analysis of tumour
cells where both nuclear DNA and the expression of oncogene
products may be determined. It also suggests that in order to
determine p53 expression a number ofantibodies maybeuseful.
2.2 Somatic alielic losses at DCC, APC, p53 and NM23-H1
tumour suppressor gene(TSG)lociintranslational cellcarcinoma
of the bladder (TCC)
S.F. Brewster',2, K.W. Brown2 & J.C. Gingell'
'Department of Urology, Southmead Hospital, Bristol BSIO
SNB;and'DepartmentofPathology, SchoolofMedicalSciences,
Bristol BS8 ITD, UK.
Thirty-one human TCCs were examined for loss of heterozy-
gosity(LOH) atfourTSGlociandchromosome lp15 usingthe
following DNA probes in a restriction fragment polymorphism
analysis: DCC [deleted in colorectal carcinoma] (18q21.3),
p15-65, SAM 1.1, JOSH 4.4, DCC 1.9 - B. Vogelstein, John
Hopkins; p53 (17pl3.1), pMCT35.1; nm23-HI (17q21.3,
pNM23-H1 - P. Steeg, NIH); APC [adenomatous polyposis
coli] (5q21), FB54D and p2.1 VNTR (llplS). Results are
expressed as number showing LOH/number informative
heterozygous samples.
Gene DCC p53 nm23-HJ APC lip15
Stage
pTa 3/14 1/5 0/13 2/9 2/8
pTI 1/5 1/2 0/4 0/4 1/4
pT2/3 4/5 1/4 2/7 0/1 3/7
Total 8/24 3/11 2/24 2/14 6/19
Grade
1 0/3 1/1 0/1 0/1 0/1
2 5/15 0/5 1/16 2/10 4/11
3 3/6 2/5 1/7 0/3 2/7
Total 8/24 3/11 2/24 2/14 6/19
LOH at p53, nm23-Hl, APC and lIpl5 occurred in 27%, 8%,
14% and 32% tumors respectively, those at nm23-Hl seen only
in high stage TCCs.
LOH atDCC, observed in 33% TCCs, occurredproportional
to increasing tumor grade and stage. Five informative grade 2
TCCs were recurrent, ofwhich threeshowed LOH atDCC; two
of the three pTa DCC-deleted tumors were recurrent. In
addition, fourRFLPmarkers locatedon 18qbothproximal and
distal to DCC (pL2.7, OLVl 1 A8, pOS-4and pLl59-I) failed to
detect LOH inTCCsheterozygousatDCC, suggestingtheDCC
TSG is the target for deletion in invasive and recurrent bladder
cancer (supported by a SWRHA research grant).
2.3 Lossofheterozygosity onchromosome 3 and 17 in head and
neck squamous cell carcinomas indicates new regions with alielic
imbalance
R.E. Adamson', C. Tsiriyotis', A.S. Jones2 & J.K. Fields'
Department of 'Clinical Dental Sciences and 20torhinolaryn-
gology, UniversityofLiverpool, POBox 147, LiverpoolL693BX,
UK.
Loss of heterozygosity (LOH) has been successfully used to
identify novel regions that may contain tumour suppressor
genes. We have investigated LOH on chromosomes 3 and 17 in1190 JOINT WINTER MEETING REPORT
squamous cell carcinoma ofthe head and neck (SCCHN) using
panels of microsatellite markers. DNA was isolated from 38
SCCHN and their respective normal tissues. All tumour
specimens used in this study contained more that 50% tumour
tissuecompared withnormal. PCRreactions wereperformed in
a 50 jLI reactionvolume andcontained 200 ngofgenomic DNA,
500ytM dNTP, 10 pmoles of each forward and reverse mic-
rosatellite primers and 0.5 units ofTaq DNA polymerase. The
DNA was amplified for 25 cycles of 94°C for 30 s at the
appropriate primerannealing temperature for 30 s and 72°C for
1 min. 10 il of the amplified PCR reaction mixture was
electrophoresed overnight on a 10% acrylamide gel. The
acrylamide gels were silver-stained.
LOH on chromosome 3 was determined with 12 microsatel-
lites and 46% (17/37) ofthe tumours analysed had LOH at one
locus. The highest incidence of LOH was found at D3S1293
(33%) at 3p24. A clear association was found between LOH on
chromosome 3 and a poor clinical prognosis, asjudged by level
ofdifferentiation, nodes at pathology and TNM staging. LOH
was also analysed on chromosome 17 with nine microsatellite
markers. LOH on 17pinSCCHNwasfoundin47% (18/38)and
often involved TP53 at 17pl3.1 (42%) but more noticeably
involved the CHRNB1 locus at l7pl2-pl .1 (56%). Fifteen
tumours also showed LOH on 17q.
These results indicate that two regions, with allelic imbalance
at 3p24 and 17pl2-pl1.1 have been found in SCCHN and these
may represent sites with novel tumour suppressor genes.
tumour types. The ERBB2 oncogene which is on chromosome
17q, is frequently amplified in breast cancer. We have shown by
Southern blot analysis that in three out of six tumours with
ERBB2 amplification that the amplicon can encompass
ERBB2, RARa and topoIIa. Interestingly, although these three
genes are co-amplified the levels ofamplification ofeach locus
within each tumour can vary. In tumour 2, all three genes are
amplified to a similar extent, whereas tumours 1 and 3 display
higher levels of topoIIa and RARoa amplification respectively.
These data suggest ampliconevolution to be acomplex process.
The amplification oftopollI would be expected to sensitise the
tumour to topo inhibitory drugs should topoIIl be expressed.
We have shown by both Western blot analysis and biochemical
assaythatamplification oftopoIIainbreastcancerscanresultin
high expression. In order to studygeneticchange at the topoIIa
locus further we have used fluorescence in situ hybridisation
(FISH). We have analysed a number of cell lines for topolI
copynumberby FISH. TheCALU3cell lineis agoodmodelfor
theamplificationobservedinbreastcancerasithasco-amplified
ERBB2, RARa and topolII. By FISH, CALU3 has five copies
oftopoIIawhereasthecelllinesL-DANandSKMEShavethree
and twocopiesrespectively. However, CALU3 expresses 10-15
times more topoIIm than the other cell lines suggesting the
possibility that gene amplification may disrupt normal control
ofgeneexpression. FISHisanidealmethodforstudyinggenetic
change as it can accurately determine gene copy number and
heterogeneity within a cell population. We are now applying
FISH to clinical samples to examine genetic change on
chromosome 17 and its histological distribution.
2.4 Deletions from chromosome 17q in ovarian cancer
I. Hickey', M.J. Murphy2, D.P. Harkin', D.W. Bell2,
S. McIlroy3, A.N. Cranston', R.J. Atkinson2, M. Humphries3,
J. Devlin' & S.E.H. Russell3
'School ofBiology and Biochemistry, 2Department ofOncology
and3Department ofMedical Genetics, The Queen's University of
Belfast.
The involvement of chromosome 17q in sporadic epithelial
ovarian cancer has been demonstrated by a number ofgroups
on the basis of loss of heterozygosity (LOH) studies. Linkage
studies in families with early onset breast-ovarian cancer have
indicated a gene (BRCA1) mapping to 17q12-21 which confers
an inherited susceptibility to breast and ovarian cancer.
We have examined 70 sporadic epithelial ovarian tumours
and matched control DNA with 20 markers from chromosome
17 (two from the short arm and 18 from the long arm).
The highest LOH was found towards the telomere with
markers in the region 17q25.
Approximately 60% oftumours displayed a pattern ofLOH
consistent with loss of an entire chromosome 17. Analysis of
nine tumours with partial 17q deletions suggests a common
regionofdeletionwhichmapsbetween themarkersTHH59 and
RMU3.
Translocations involving chromsome 17 were observed in a
number of cell lines derived from epithelial ovarian tumours.
2.5 Molecular cytogenetic analysis of the topoIoa locus
W.N. Keith, F. Douglas & J. Coutts
Department ofMedical Oncology, CRC Beatson Laboratories,
Garscube Estate, Switchback Road, Bearsden, Glasgow G61
IBD, UK.
The levels of topolIa within a cell will in part determine its
sensitivity to the cytotoxic effects of topoisomerase inhibitory
drugs. The topolII locus is situated on chromosome 17q in a
region frequently altered during the development of many
2.6 p53 gene mutation predicts response ofcolorectal cancer to
chemotherapy
M. Pickard, M. Brett, B. Green, A. Howel-Evans, G. Poston &
A. Kinsella
Department ofSurgery, Liverpool University, Liverpool, UK.
Mutation of the p53 gene is the most common cancer related
genetic change known at the gene level and occurs in 70% of
colon carcinomas. Wild type p53 produces a nuclear phospho-
protein, believed tobeinvolvedincellcycleregulation, andhasa
very short halflife. Mutant forms ofp53 have a longer halflife
and are therefore detectable using immunohistochemistry. The
ABC method of immunohistochemical staining was used on
paraffin sections ofthe primary tumours to investigate whether
p53 gene mutation can be used to predict response to chemo-
therapy. Twoindependentobservers scoredthesectionspositive
or negative for the presence or absence of p53 protein,
respectively.
Thirty-three colon carcinoma patients were tested who had
each received 5-FU (370 mg/m2) and Folinic acid (200 mg/M2)
for five consecutive days every 28 days for up to 6 months of
treatment. CAT scans ofanindex lesion after 3 and 6months of
treatment showed either response (>50% regression), static
disease or progressive disease. Results were as follows:
Mutantp53 Wild type p53
Response/Static disease
Progressive disease
4
12
12
5
Mutant types were significantly less likely to respond to
chemotherapy than wild type (P = 0.011, Fisher's exact test)
and response was unrelated to age, sex or tumour grade.
Assessment of p53 status may assist in patient selection for
bimodulated 5-FU chemotherapy.JOINT WINTER MEETING REPORT 1191
2.7 Over-expression and amplification of the MDR1 gene in
the doxorubicin resistant human bladder cancer cell line,
KK47/ADM
S.C. Clifford', S. Naito3, D.E. Neal2 & J. Lunec'
'Cancer Research Unit and 2Department of Surgery, Medical
School, University ofNewcastle upon Tyne, UK; and 3Depart-
ment of Urology, Kyushu University, Fukoka, Japan.
Establishment of the drug resistant human bladder cancer
cell line, KK47/ADM has recently been described. Following
stepwise selection in increasing concentrations of doxo-
rubicin, KK47/ADM was 271 times more resistant to doxo-
rubicin than its KK47 parent. Preliminary characterisation
revealed KK47/ADM to have a classical multidrug resistance
phenotype. Elevated levels of P-glycoprotein were observed
together with decreased drug accumulation caused by an
increased active efflux, which was reversed in the presence of
verapamil. Cross resistance to the anthracyclines, vinca
alkaloids and etoposide (but not cisplatin or methotrexate)
was observed (Kimiya et al., J. Urol., 148, 441-445, 1992).
mRNA levels of the MDR1 gene (which encodes P-glyco-
protein) were determined by a quantitative PCR-based tran-
script assay and Northern blot hybridisation. While the
sensitive parental line, KK47, had low levels similar to those
seen in primary superficial bladder tumors, from which it was
derived, the KK47/ADM resistant line had 55-fold higher
levels (P = 0.0023), more comparable with the levels found in
high MDR1 expressing adrenal tissue and 10-fold higher
than any bladder tumor sample we have analysed. Southern
blot analysis of MDR1 gene copy numbers revealed a 5-fold
increase in the gene copy number of the KK47/ADM cell-
line when compared to that of its parental KK47 line.
Results thus show increased transcription to be the predom-
inant mechanism of MDR1 overexpression in the KK47/
ADM cell line.
Verapamil could not completely overcome the resistance of
KK47/ADM to doxorubicin (Kimiya et al.) suggesting that
while overexpression of the MDR1 gene is the principal
mechanism of drug resistance, other mechanisms may be
present which play a smaller but none the less contributory
role. Transcript levels of the MRP gene (associated with
non-P-glycoprotein mediated MDR) were determined and
found to be 1.7-fold higher in KK47/ADM than its parental
line, though this result was not significant (P = 0.26).
2.8 N-myc gene copy number in neuroblastoma cell lines and
resistance to experimental treatment
A. Livingstone', R.J. Mairs', J. Russell', J. O'Donoghuei,
M.N. Gaze2 & T.E. Wheldon'
'Department of Radiation Oncology, University of Glasgow,
Garscube Estate, Glasgow G61 JBD; 2The Meyerstein Institute
of Clinical Oncology, The Middlesex Hospital, Mortimer
Street, London WIN 8AA, UK.
The N-myc oncogene is amplified in approximately 30% of
neuroblastoma. It is well established that cases of neuroblas-
toma with amplified N-myc have markedly poorer prognosis
than those in which N-myc copy number is not elevated. The
mechanism for this association is not known but may be
related to cellular resistance to radiation or cytotoxic drugs.
Seven human neuroblastoma cell lines were used to investi-
gate the relationship between N-myc copy number or expres-
sion and sensitivity to ionising radiation and to cisplatin.
N-myc copy number was assessed by Southern blotting
and hybridisation using the p-Nbl probe. The signal pro-
duced by DNA from the cell lines was compared with that of
single copy N-myc from normal human placental DNA. A
range of N-myc copy numbers from 1-800 was found. Ex-
pression levels of N-myc m-RNA were compared by 'dot
blotting' and subsequent hybridisation to the p-Nbl probe.
Radiosensitivity was assessed by surviving fraction at 2 Gy
(SF2) following 'Co gamma irradiation. Values ranged from
0.13-0.52. Sensitivity to cisplatin was indicated by com-
parison of iso-effective concentrations (concentration requir-
ed to produce 1 log cell kill). These ranged from 7.5-13 t.M.
Cisplatin studies showed a correlation between N-myc
copy number (though not expression) and resistance to this
drug. If this relationship is causal it may explain why treat-
ment fails in those patients with elevated N-myc copy
number. However, no correlation was found between N-myc
copy number or expression and sensitivity to radiation. It is
possible that N-myc amplification confers resistance to some
but not all treatments used in the therapy of neuroblastoma.
Further investigations along these lines may lead to the
investigation of agents which are most appropriate for the
treatment of neuroblastoma with amplified N-myc gene.
3.1 The activity of deoxyspergualin in multidrug resistant
cells
J.A. Holmes & P.R. Twentyman
MRC Clinical Oncology & Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
15-deoxyspergualin (DSG) is a synthetic analogue of the
immunosuppressive antitumour antibiotic spergualin that was
first isolated from culture filtrates of Bacillus laterosporus
(Takeuchii et al., J. Antibiot., 34, 1619, 1981). The compound
has been shown to possess potent in vitro and in vivo anti-
tumour activity and is currently in the NCI decision network.
DSG has also been shown to bind to the human constitutive
heat shock protein Hsp7O. Cyclophilin (the cyclosporin A
(CsA) binding protein), FK506 binding protein, and heat
shock proteins are all involved in the regulation of protein
folding, which suggests that a common mechanism of action
may exist for these immunosuppressants (Nadler et al.,
Science, 258, 484, 1992). As CsA and FK506 are natural
products possessing potent immunosuppressive properties
and also the ability to act as modifiers of classical multidrug
resistance (MDR), we decided to examine the activity of
DSG in MDR cells. DSG contains the polyamine spermidine
within its structure and can therefore be considered a sper-
midine analogue. Bovine serum (BS) amine oxidase catalyses
the oxidative deamination of spermidine to produce amino-
aldehyde, ammonia and H202. It is thought that these amino-
aldehydes are responsible for the toxicity of polyamines in
vitro in the presence of BS (Kunimoto et al., J. Antibiot., 38,
899, 1985). For this reason all experiments involving incuba-
tion of cells in medium were performed in duplicate using
both BS and horse serum (HS), which is low in amine
oxidase content. We used the mouse tumour cell line EMT6/
P and the human small cell lung cancer line H69/P together
with their P-glycoprotein (Pgp) hyperexpressing sublines
EMT6/AR1.0 and H69/LX4. Cytotoxic effects were deter-
mined using the MTT colorimetric assay with a 3 day
(EMT6) or 6 day (H69) assay duration. Mean IC50 values in
BS were 1.6, 2.8, 11, 15jig/ml for EMT6/P, EMT6/AR1.0,
H69/P and H69/LX4. Corresponding values in HS were 6, 8,
22, 40tsg/ml respectively. The lines are therefore 2-4 fold
more sensitive to DSG in BS than in HS. However, the
MDR sublines showed only minimal cross-resistance to
DSG. At 5-100 jig/ml, DSG did not enhance the accumula-
tion of [3H]daunorubicin in EMT6/AR1.0. Furthermore,
DSG (0.5-10jg/ml) did not alter the IC50 of doxorubicin in
H69/LX4 cells. Pgp in membranes from H69/LX4 cells was
photoaffinity-labelled with [3H]azidopine. DSG did not
inhibit this labelling. Although therefore DSG appears to
exert its immunosuppressive actions via a similar mechanism
to that of CsA and FK506, our results show that it does not
share their ability to modify Pgp-mediated MDR. They also
confirm that the cytotoxicity of DSG is increased in the
presence of BS compared to HS.1192 JOINT WINTER MEETING REPORT
3.2 Competitive inhibition by genistein of the ATP-dependent
daunorubicin transport in an MRP overexpressing, MDR lung
cancer cell Une
C.H.M. Versantvoort, H.J. Broxterman, J. Lankelma, N.
Feller & H.M. Pinedo
Department of Medical Oncology, Free University Hospital,
Amsterdam, The Netherlands.
In several multidrug resistant tumor cell lines without over-
expression of P-glycoprotein (non-Pgp MDR), a decreased
accumulation of drugs has been shown to contribute to the
resistance. The daunorubicin accumulation in the GLC4/
ADR non-Pgp MDR lung cancer cells was shown to be
decreased due to an enhanced energy-dependent DNR efflux.
The GLC4/ADR cells do overexpress the MRP gene"2, which
was recently discovered to be overexpressed in another non-
Pgp MDR lung cancer cell line. We now further charac-
terised the daunorubicin transport and its dependence on
cellular ATP levels. Furthermore, the effects of the iso-
flavonoid genistein on the decreased daunorubicin accumula-
tion in the GLC4/ADR cells were studied.
As measured by a relative increase in steady-state accumu-
lation of daunorubicin, the active efflux of daunorubicin out
of the GLC4/ADR cells appeared to be a saturable process
with an apparent KM value of DNR of 1.4gM. Genistein
reversed the decreased daunorubicin accumulation in the
GLC4/ADR and several other non-Pgp MDR cell lines. In
contrast, the daunorubicin accumulation in Pgp MDR cell
lines was not increased by 200lIM genistein. Furthermore, the
apparent KM value of daunorubicin in the GLC4/ADR cells
was increased by genistein, suggesting that this agent is a
competitive inhibitor of the active DNR transport.
Marked inhibition of the daunorubicin transport activity
was found at cellular ATP concentrations below 2 mM. Thus
the daunorubicin transport activity in intact GLC4/ADR
cells is already impaired by a rather modest cellular ATP
depletion. This might open ways to enhance the toxic effects
of drugs in MDR cells.
1. Cole, S.P.C. & others. (1992). Science, 258, 1650-1654.
2. Zaman, G.J.R. & others. (1993). Cancer Res., 53, 1747-1750.
3.3 Influence of temperature, pH and the chemical modifier,
genistein, on intracellular anthracycline distribution in non-Pgp
MDR cell line, COR-L23/R
T. Rhodes & P.R. Twentyman
MCR Clinical Oncology & Radiotherapeutics Unit, Hills
Road, Cambridge CB2 2QH, UK.
COR-L23/R is a human MDR cell line which does not
overexpress the MDR-1 gene or its product, P-glycoprotein
(Pgp), but has high levels of the alternative transporter
molecule, MRP (Cole et al. Science, 258, 1650, 1992). Fol-
lowing acute exposure to doxorubicin (DOX), the total cel-
lular drug accumulation and intracellular drug distribution
are strikingly different in COR-L23/R compared with the
parental line COR-L23/P. It is known that cellular accumula-
tion of DOX is pH and temperature dependent and that
extracellular pH in tumours is frequently 0.5 pH units lower
than in normal tissues. We have therefore compared the
effects of changing temperature and/or extracellular pH on
the anthracycline distribution in COR-L23/P and COR-L23/
R cells. Cells grown on glass coverslips were treated with
DOX (20 jLM, 1 h), rinsed in ice-cold PBS, inverted onto a
slide and visualised using the Biorad MRC-600 laser-assisted
confocal fluorescence microscope. In COR-L23/P at 37°C
and pH 7.4, fluorescence was predominantly nuclear with
only sparse, punctate cytoplasmic fluorescence. By contrast,
fluorescence in COR-L23/R was mainly confined to groups
of perinuclear cytoplasmic vesicles with little nuclear
fluorescence. In COR-L23/P, changing pH at 37°C from 5.8
to 8.6 resulted in increased nuclear fluorescence without
major changes in distribution. Marked alterations were how-
ever observed in distribution with changing extracellular pH
in the resistant line. At 37C and pH 5.8, fluorescence was
weak and wholly restricted to the cytoplasm, whereas at pH
8.6 it was stronger, mainly nuclear and only weak cytoplas-
mic fluorescence was observed. At a temperature of 22C and
pH 8.6 the fluorescence distribution in COR-L23/R became
identical to that in COR-L23/P. This result could not be
achieved by low temperature alone. A reduction in tempera-
ture to 4'C (at pH 7.4) resulted in low fluorescence, confined
to the cytoplasm, in both the resistant and parental cells. It
appears therefore that drug accumulation and distribution in
COR-L23/R cells are dependent upon metabolic rate and
upon extracellular pH, possibly due to pH-dependent
changes in DOX ionisation.
A number of chemical agents have been suggested as
modifiers of non-Pgp MDR and an agent of current interest
is the tyrosine kinase inhibitor genistein, which has been
found to alter intracellular DOX distribution (Takeda et al.,
Proc. AACR, 33, 476, 1992), and daunorubicin (DNR)
accumulation (Versanvoort et al., Br. J. Cancer, Dec, 1993)
in other non-Pgp MDR cell lines but not classic MDR cell
lines. In COR-L23/R a non-toxic dose of genistein (400pM,
1 h) completely restored DNR accumulation to control levels,
whilst having no effect on the parental line. Confocal studies
observing the effects of genistein on the intracellular DNR
distribution in COR-L23/R confirmed the increased levels of
drug and also patterns of intracellular distribution similar to
those in parental cells.
3.4 In vitro modification of resistance to MDR-related drugs
in acute myeloid leukaemia (AML)
J. Sargent, A. Elgie, P. Alton & C. Taylor
Haematology Research, Pembury Hospital, Pembury, Kent
TN2 4QJ, UK.
The multidrug resistance (MDR) phenotype has been shown
to effect the uptake and accumulation of anthracyclines and
etoposide, the drugs used in first line treatment of AML.
Tested against cell lines, verapamil (Ver), cyclosporin A
(CsA) and tamoxifen (Tam) have been shown to chemosensi-
tize cells which are resistant to these drugs.
We describe a study to test the ability of these agents to
modify in vitro resistance to doxorubicin (Dox), mitoxan-
trone (Mit) and etoposide (VP16) using fresh blast cells from
18 patients with AML, 13 on presentation and five after
previous treatment. The MTT assay was used to measure cell
viability after 48 h continuous drug exposure. Log dose res-
ponse curves were constructed for each test and if >30% of
cells survived at 1 gLg/ml for the anthracyclines and 25jig/ml
for VP16 the cells were deemed resistant. The effect of the
modifier was determined by comparing the area under the
curve for drug + modifier with that of drug alone. One hun-
dred and nineteen comparisons were made overall; 41
showed an increase in sensitivity on co-incubation with a
modifier. CsA (4pM) was the most effective sensitizer show-
ing significantly increased cytotoxicity in 24/41 (59%) com-
parisons (P<0.03). Indeed, blast cells from 7/8 patients
resistant to Dox were rendered sensitive with the addition of
CsA. Ver (3.3 isg/ml) increased sensitivity in 12/53 (23%)
cases and Tam (10 JLM) in 4/25 (16%) cases. The effect of
individual modifiers was variable between patients ranging
from 7/9 tests in one patient to only 1/9 tests in another.
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chemosensitization in the group of patients who had pre-
viously received treatment.
The expression of the MDR product P-glycoprotein (Pgp)
was assessed using immunocytochemistry on cytospin prepar-
ations of the cell suspension used in the MTT assay and the
monoclonal antibodies C219, JSB-1 and MRK16. Prelimin-
ary data suggest no correlation between Pgp expression and
chemosensitization. More sensitive techniques may be requir-
ed to establish Pgp expression in the cells exhibiting resis-
tance modification.
These data suggest CsA may be the best chemosensitiza-
tion agent overall in AML. They also support the clinical use
of drug modification regimes identified by in vitro screening
techniques for individual patients.
3.5 Resistance to platinum-based drugs in ovarian carcinoma
J. Sargent, A. Elgie, C. Taylor, P. Alton & J.G. Hill
Haematology Research, Pembury Hospital, Pembury, Kent
TN2 4QJ, UK.
Resistance to front line agents, such as cisplatin and its
analogue carboplatin, remains a major problem in the treat-
ment of ovarian cancer. This resistance, whether inherent or
acquired, is thought to be due to increased intracellular
detoxification.
We describe a study firstly, to identify resistance to these
agents and secondly, to attempt to modify this resistance in
vitro. One hundred and sixty-seven samples of ascitic fluid
and 160 biopsy samples from 206 patients with ovarian
adenocarcinoma were continuously exposed to four concen-
trations of cisplatin and carboplatin for 48 h. The cell
viability was then assessed using the MTT assay. The success
rate for the assay is currently 80%. Log dose response curves
were calculated and if >30% of cells survived at 51ag/ml
cisplatin or 50tLg/ml carboplatin, the cells were deemed to be
resistant. Cisplatin and carboplatin produced a similar cell
kill in 76% of cases tested. The resistance rates for these
agents in a group of untreated patients were 71% for cis-
platin and 54% for carboplatin; the resistance rate for carbo-
platin increased to 65% in a group of patients who had
received previous therapy. The assay results showed a
positive correlation with the clinical outcome in 18 of 25
(60%) untreated patients (P= 0.018). Sixty percent of
patients treated with a drug to which their tumour was
sensitive showed a complete clinical response compared with
only 10% of those whose tumour was resistant.
One of the mechanisms involved in platinum resistance is
thought to be increased detoxification through the gluta-
thione (GSH) pathway. We attempted to reduce intracellular
levels of GSH in vitro using buthionine sulfoxamine (BSO;
100l M) and inhibit glutathione-S-transferases (GSTs) with
ethacrynic acid (ETH; 6.5 LM). Modification effect was
assessed by comparing the area under the curve with that of
drug alone. Forty-nine comparisons were made of the effect
of these agents on cisplatin and carboplatin cytotoxicity
using fresh cells from 13 patients. There was a marked
variation between patients in the effect of co-incubating with
BSO or ETH. BSO increased the sensitivity to carboplatin in
three patients and ETH increased sensitivity to cisplatin in
two patients. Indeed, in three patients, resistant cells were
rendered sensitive by chemosensitization.
Variation between patients indicates the importance of in
vitro screening for an effective modifier before treatment and
these results support the clinical use of these resistance
modifiers in the treatment of ovarian cancer.
3.6 Factors involved in cellular resistance to the bioreductive
drug E09 and related mitosenes
I.J. Stratford', N. Robertson', A. Haigh', C. Moody2, P.
Workman3 & G.E. Adams'
'MRC Radiobiology Unit, Chilton, Didcot, Oxon OXJJ ORD;
2Department of Chemistry, University of Loughborough,
Loughborough LEIJ 3TU; 3Zeneca Pharmaceuticals, Mere-
side, Alderley Park, Macclesfield, Cheshire SKIO 4TG, UK.
Twenty-three human tumour cell lines (lung, breast and
colon) have been evaluated for their sensitivity to the
quinone based anti-cancer drug E09. Sensitivity has been
compared with the intra-cellular levels of DT-diaphorase and
cell lines showing the lowest enzyme activity are the most
resistant to E09. Dicoumarol, an inhibitor of DT-diaphorase,
renders cells containing high levels of enzyme resistant to
E09. Further, using pairs of Chinese hamster cells with vary-
ing levels of DT-diaphorase, resistance is observed in those
cells with low levels of reductase. Taken together these results
are consistent with a dominant role for two-electron reduc-
tion, catalyzed by DT-diaphorase, in the bioactivation of
E09.
Novel mitosenes related to E09 and mitomycin C have
been synthesized. One of these (RB91008, an aziridinyl cyclo-
propamitosene) is 50 x more potent than E09 in V79 cells
(3 h exposure in air). Treatment of cells with dicoumarol
protects against the action of RB91008. Replacement of the
aziridine in RB91008 with methoxy only has a slight effect on
the ability of the compound to act as a substrate for DT-
diaphorase but potency is reduced 1000 x. These results
illustrate the importance of reductive activation for control-
ling toxicity but also suggest that other processes can play a
crucial role in controlling cellular resistance to these quin-
inoid compounds.
3.7 Enhancement of bioreductive drug activity in experimental
murine tumours by the nitric oxide synthase inhibitor nitro-L-
arginin
G.E. Adams, P.J. Wood, J. Sansom, S. Butler & I.J. Stratford
MCR Radiobiology Unit, Chilton, Didcot, Oxon OXII ORD,
UK.
Nitric oxide is an endogenous vasodilator responsible for
maintaining blood vessel potency, and is generated in vivo
from L-arginine by nitric oxide synthase (NOS). NOS
activity may be inhibited by agents such as nitro-L-arginine
(NOARG) resulting in vasoconstriction. We have recently
demonstrated using 31p mrs that the transplantable murine
tumour SCCVII and various spontaneous murine mammary
adenocarcinomas can respond to NOARG. This was observ-
ed as a change in phosphorous metabolism indicating in-
creased tumour hypoxia.
The induction of tumour hypoxia is sufficient to activate
bioreductive drugs, in particular the agent RB 6145 deve-
loped in this Laboratory. The drug is a substituted 2-
nitroimidazole which, on reductive activation by cellular
reductase, is converted to a powerful DNA cross-linking
agent. It is highly active in various experimental solid
tumours.
Treatment in vivo of the KHT murine tumour, by combin-
ation of nitro-L-arginine and RB 6145, produced a large
anti-tumour effect when measured by a post-treatment exci-
sion cell survival assay. Single doses of RB 6145, in the range
100-300 mg/kg, were followed 15 minutes later by single
doses of nitro-L-arginine 5-20mg/kg. For the higher dose
ranges, tumour cell-kill as measured by relative cell survival,
exceeded five decades in the majority of tumours.
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will be used to illustrate potential clinical value of this ap-
proach to overcome relatively inaccessible and chemo-resis-
tant tumour cells.
3.8 Effect of salvage pathways on drug resistance
M. Pickard & A.R. Kinsella
Department of Surgery, University ofLiverpool, PO Box 147,
Liverpool, L69 3BX, UK.
Resistance of human tumour cells to chemotherapeutic
agents has been a common clinical problem. The effect of
nucleoside salvage in combination with the antimetabolites
5-fluorouracil, N-(phosphonacetyl)-L-aspartate and metho-
trexate was investigated. A series of cell lines of common
genetic origin was used which exhibit a range of differing
phenotypes from normal (KMS), through immortalized
(KMST) to aggressively tumourigenic (KN-NM) (Namba et
al., 1987) (Kinsella et al., 1990).
Kinsella and Haran (1991) demonstrated that the intrinsic
sensitivities of methotrexate and PALA showed increasing
resistance to parallel increasing tumourigenicity with these
cell lines and this was unrelated to amplification of the
respective target genes. Dipyridamole, a nucleoside transport
inhibitor, was used in combination with the respective drugs
in standard survival assays, in normal foetal bovine serum, to
assess the contribution of the salvage pathways to resistance.
The KN-NM tumourigenic cell line was totally resistant to
PALA up to a concentration of 1 mM compared to an LD50
of 50 gM after the addition of dipyridamole. The KMS nor-
mal cell line had an LDs, of 5 JAM and 60 JAM respectively in
the presence and absence of dipyridamole. Methotrexate gave
an LDm of 2.5 JAM without dipyridamole and 0.7 JAM with
dipyridamole for the KN-NM cell line. This difference has
been eradicated with the KMST cell line which gave an LD50
of 0.4 JAM both with and without dipyridamole. The KN-NM
cell line had an LD50 of 2.5 JAM with 5-FU both with and
without dipyridamole which fell to 0.9 JAM 5-FU with and
without dipyridamole for the KMS normal cell line. These
data suggest that the salvage pathways are having a marked
effect on resistance of the cell lines to PALA, only a moder-
ate effect with methotrexate and no effect with 5-FU.
Keywords: Methotrexate; PALA; 5-Fluorouracil
3.9 Constitutive and induced heat shock protein levels in
human cancer cell lines
E.H. Richards', J.R.W. Masters' & J.A. Hickman2
'University College London, 3rd Floor, 67 Riding House St.,
London WIP 7PN; 2CRC Molecular and Cellular Pharmaco-
logy Group, School ofBiological Sciences, University of Man-
chester, Manchester M13 9PT, UK.
Testicular germ cells are acutely sensitive to damage induced
by chemotherapeutic drugs, irradiation and heat. This res-
ponse to various forms of stress may explain why metastatic
testis tumours, in contrast to most other types of advanced
cancer, can be cured in over 80% of cases using cisplatin-
based combination chemotherapy. To investigate the molecu-
lar basis of the stress response, we compared the sensitivities
in vitro of human testis and bladder cancer cell lines to
chemotherapeutic drugs and heat shock, and measured their
constitutive and induced levels of heat shock proteins (HSP)
and ability to develop thermotolerance.
Reflecting their chemosensitivity in vivo, the testis cancer
cells are hypersensitive to chemotherapeutic drugs (Masters,
J.R.W. et al. IJC, 53, 340; 1993). Comparing their sensitivity
to heat shock, the percentage clonogenic cell survival for the
bladder lines ranged from 51.6-69.3% in the bladder lines
compared to only 0.8-15.6% in the testis lines following a
30min exposure to 45°C. Constitutive levels of HSP70 (72
and 73) and HSP90 showed no association with heat sen-
sitivity, but HSP27 was virtually undetectable (Western
blotting/scanning densitometry) in testis cancer cells, in con-
trast to the high levels detected in bladder cancer cells.
Following an equitoxic heat shock, HSP72 synthesis con-
tinued for 10h in the bladder line HT1376 (45°C/60min)
compared to only 4h in the testis line 833K (45°C/15min).
Thermotolerance also differed between the two cell types.
Following a priming heat shock at 42°C, thermotolerance
developed more rapidly and was prolonged in the bladder
line HT1376 compared to the testis line 833K.
In conclusion, testis tumour cells are hypersensitive to heat
shock, are less able to develop thermotolerance and express
HSPs, and contain low levels of HSP27.
3.10 Cyclophosphamide pharmacokinetics in children: sources
of inter-patient variation
S.M. Yule', A.V. Boddy2, M. Cole3, L. Price', R. Wyllie',
A.D.J. Pearson' & J.R. Idle2
Departments of 'Child Health, 2Pharmacological Sciences and
'Medical Statistics, The Medical School, Newcastle upon Tyne
NE2 4HH, UK.
Cyclophosphamide (CP) remains widely used in the treat-
ment of paediatric malignancy. Hepatic metabolism of CP is
necessary to produce the active alkylating species phosphor-
amide mustard.
Several authors have demonstrated considerable inter-
patient variability in CP pharmacokinetics in adults with a
single study linking these differences to the results of treat-
ment. Cyclophosphamide kinetics were measured in 33 child-
ren (age 2 months-18 years). Each child received the drug as
a one hour infusion (dose 0.37-2.49 g/m2). Plasma levels of
CP were measured using a quantitative Thin Layer Chroma-
tography technique. The plasma half-life (t1/2), Volume of
Distribution (Vd) and Clearance (Cl) were obtained from a
one compartment model with first order elimination kinetics.
Considerable inter-patient variation was seen. Cyclophos-
phamide t1/2 exhibited 14-fold variation with, seven-fold
variation observed in Cl and four-fold variation in Vd.
Cyclophosphamide t1/2 increased with age, dose (mg/M2),
and concurrent administration of allopurinol. The t1/2 in
children receiving repeated courses of CP was shorter than
those receiving the drug for the first time. Children who
received dexamethasone prior to the study exhibited an in-
creased Cl.
This study documents the extent of inter-patient variation
amongst children with cancer. The prolonged t1/2 seen at
higher doses may reflect saturation of hepatic metabolism.
Other differences may be the result of inherited variation in
cytochrome P450-linked enyzme activity. The influence of
allopurinol and dexamethasone may be due to hepatic
enzyme inhibition and induction respectively. This study sug-
gests that concurrent medication may alter CP pharmaco-
kinetics and thus therapeutic effect.
4.1 Phosphorylation of the human oestrogen receptor
S. Ali', P. Pacel, D. Metzger2, P. Chambon2 & R.C. Coombes'
'Department of Medical Oncology, Charing Cross Hospital,
London W6 8RF, UK; 2LGME-CNRS, U184 de l'INSERM,
Faculte de Medicine, 11 Rue Humann, 67085 Strasbourg.
The importance of the oestrogen receptor (ER) in breast
cancer is well established. Molecular cloning and functional
analyses have shown that the ER is a ligand-inducible tran-
scription factor which activates transcription by binding to
short DNA palindromic elements in promoters of responsive
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We (and others) have recently shown that the ER is phos-
phorylated upon binding oestradiol. We have further shown
that the human ER is phosphorylated on 4-5 sites in the
presence of oestradiol and that the anti-oestrogens tamoxifen
and ICI 164,384 also induce ER phosphorylation, although
at much lower levels than oestradiol. Phosphoamino-acid
analysis shows that most of these sites are serine residues.
Using deletional analysis we have mapped the N-terminal-
most phosphorylation site to serine 118. The region (region
A/B), containing serine 118 is required for correct promoter
and tissue-specific trans-activation by human ER and muta-
tion of serine 118 drastically reduces trans-activation by
human ER, but has no effect on DNA or hormone binding
by the ER.
We have subsequently also shown that the ER can be
phosphorylated in vitro by at least three protein kinases
involving different signal transduction pathways.
These results and their importance for the regulation of
ER function will be discussed.
4.2 Basic fibroblast growth factor-binding proteoglycans of
human breast
P.J. Browne', J.J. Gomm', R.C. Coope', R.C. Coombes' &
R.M. Mason3
'Department of Medical Oncology and 'Department of Bio-
chemistry, Charing Cross and Westminister Medical School,
London W6 8RP, UK.
In the normal human breast basic fibroblast growth factor
(bfgf) is concentrated in the myo-epithelial cell layer. To
further define the role of bfgf in breast growth and develop-
ment, we measured the ability of proteoglycans (PGs) pro-
duced by normal and malignant human breast cells to bind
bfgf. Human recombinant bfgf was linked to a solid support,
packed into a mini-column and the elution profiles of 35S-
labelled PGs in a stepwise NaCl concentration gradient were
determined. The malignant breast cell line, MCF-7 and the
normal, immortalised breast cell lines, HBL-100, MCF-1OA
and MTSVI-7 were all found to express bfgf-binding PGs
with a similar range of affinities. The PGs derived from the
culture medium contained a greater proportion of higher
affinity molecules than the cell-associated PGs. To investigate
normal breast cells, reduction mammoplasty tissue was
digested with collagenase following which pure populations
of epithelial and myo-epithelial cells were prepared from
trypsin-disaggregated organoids by immunomagnetic sorting
using the Epithelial Membrane Antigen (EMA) for epithelial
cells and the CD10 marker for myo-epithelial cells. Cultures
were also established from the collagenase digests by selecting
those cells capable of adhering rapidly to a plastic substrate.
These cultures, designated stromal, had a fibroblastic mor-
phology and were negative for EMA, cytokeratins 14 and 18
and collagen IV. The stromal cultures grew extremely well
while the epithelial and myo-epithelial cultures proliferated
more slowly and died out after 4-5 weeks. We have demon-
strated bfgf-binding PGs in stromal and epithelial cell cul-
tures but, to date, we have been unable to do so with
myo-epithelial cultures. We hope to overcome this problem
by modifying the immunomagnetic sorting process and/or the
culture medium.
4.3 Expression of variant fibroblast growth factor receptors
in human breast
Y.A. Luqmani, C. Mortimer, G. Bansal, L. Buluwela &
R.C. Coombes
Department of Medical Oncology, Charing Cross Hospital,
London, UK.
The widely distributed super family of heparin binding
FGF's influence a diverse range of cellular activities exerted
through specific cell surface receptors, for which at least four
separate genes have been cloned: all of these include three
extracellular Ig-like loops, a transmembrane region and a
split cytoplasmic tyrosine kinase encoded domain. Several
alternatively spliced mRNA isoforms have been identified.
We have studied (using PCR) the expression, in RNA
extracted from a large number of primary breast cancers,
normal breast and cell lines, of two such variants affecting
the extracellular Ig-like region. Both two loop and three loop
forms of FGFRI were found in all samples, with the former
as the predominant type in cancers as compared to normal
breast (p<0.02): also reflected in the cell lines. Patients with
high 2/3 loop tumour ratios had reduced relapse free survival
(p<0.007) particularly in the ER negative sub-group. Alter-
native usage of an exon loop results in the described BEK
and SAM variants of FGFR2, both of which were found to
be present in all tissues examined. SAM was predominantly
expressed in cell lines of epithelial lineage, and only 4/32
(including two breast) lines expressed both variants
significantly. Ligand specificity between these forms may be
implicated in paracrine regulatory mechanisms involving for
example, interaction with stromal derived KGF which binds
only the SAM variant.
4.4 mRNA localisation for FGF's and their receptors in
resected adenocarcinomas of the human pancreas
H.Y. Leung'2, C.M. Hughes', G. Kl6ppel3, R.C.N. William-
son2 & N.R. Lemoinel
'ICRF Oncology Group, 'Department of Surgery, Hammer-
smith Hospital, London, UK; 'Academic Hospital Jette,
Laarbeeklaan 101, Brussels.
Using a panel of 14 human pancreatic cancer cell lines, we
have previously identified a characteristic pattern of expres-
sion for the first seven members of Fibroblast Growth Fac-
tors and their four receptors. We now report our observa-
tions from in situ hybridization (ISH) examination on a
collection of archival paraffin embedded blocks of human
pancreatic cancer. The non-radioactive digoxigenin system is
used to generate specific antisense orientated riboprobes for
FGFI and FGF2, and the four FGFRs (FGFR1, 2, 3 and
4). The corresponding sense strand riboprobes were used as
controls. Sections from the blocks were processed according
to standard ISH protocol and signals were generated with
alkaline phosphatase conjugated anti-digoxigenin antibody.
We confirmed the expression of both FGF/FGFR by
tumour cells, with the presence of a potential autocrine loop
activity in 46% of the cases studied. FGF2 and FGFR3 were
the most commonly expressed ligand and receptor (46% and
76% respectively). The acinar cells were found to have a
heterogeneous expression pattern for FGFRs while duct cells,
islet cells and stromal components were negative.
In summary we report an additional piece of evidence
strongly suggesting an important role of FGFs and their
receptors in human pancreatic adenocarcinoma.
4.5 Differing behaviour of colon carcinoma cells and correla-
tion with epidermal growth factor receptor ligand expression
N. Solic, S.J. Holt, A. Richter, J. Collins, R. Adam, P.
Alexander & D.E. Davies
CRC Medical Oncology Unit, Southampton General Hospital,
Southampton S09 4XY, UK.
Recent studies (Saeki, T., Stromberg, K., Qi, C-F. (1992).
Cancer Research, 52, 3467) have reported expression of
amphiregulin (AR) in normal colon and well differentiated
colonic tumours whereas transforming growth factor alpha
(TGFa) expression is found in poorly differentiated tumours.
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growth factor receptor (EGF-R) ligands may be associated
with progression from premalignant to malignant carcinoma
of the colon.
We have investigated EGF-R ligand expression and their
contribution to the growth and differentiation of colon car-
cinoma cells (GP cells) which we have recently established in
culture. Within the cell culture, two distinct sub-types of cells
with differing morphologies could be identified. One group of
cells tended to form multilayered colonies whereas the other
group was more fibroblastic in appearance. This morpho-
logical difference persisted when individual cells were cloned.
Two of these clones, identified as GP5d (multilayered) and
GP2d (fibroblastic), were shown to have identical karyotypes,
both possessing a deletion on the long arm of chromosome 5.
Both clones grew as xenografts in nude mice, GP2d formed a
well differentiated tumour while GP5d formed an undiffer-
entiated invasive tumour. The clones were shown by RT-
PCR and immunocytochemical staining to express three
ligands for EGF-R, namely AR, TGFa and heparin-binding
EGF, as well as the receptor itself. Whereas AR expression
was comparable in the two clones, GP5d expressed a higher
level of TGFa. Although proliferation of the cells in serum
free medium was slightly enhanced in the presence of EGF
(1-25 ng/ml), by far the most striking effect of this growth
factor was on the morphology of the cells causing them to
spread and become more flattened in appearance. This
change was shown to be associated with a redistribution of
desmosomal proteins. The effect was also observed using
TGFa but not using comparable doses of recombinant
amphiregulin (as evaluated in a standard mitogenesis assay
using NR6/HER fibroblasts).
The availability ofcells derived from the same tumour with
persistent differences in behaviour may provide a useful ex-
perimental model for the further study of oncogenes and/or
transcription factors in colon carcinoma and may provide
new insight into factors controlling progression of this
disease.
5.1 Correlation of EGF-induced protein tyrosine-phosphory-
lation with loss of tumour cell adhesion in vitro
T. Gulliford & R.J. Epstein
CRC Laboratories, Department ofMedical Oncology, Charing
Cross Hospital, London W6 8RF, UK.
Human cancer metastasis displays 'soil-and-seed' characteris-
tics which may reflect tumour cell expression of specific
cytokines and/or adhesion molecules. Here we report that
A431 human squamous carcinoma cells undergo striking
morphologic and adhesive changes in vitro within 5 min of
exposure to epidermal growth factor (EGF). Loss of cell
adhesion closely parallels the dose- and time-dependency of
EGF receptor autophosphorylation. Equally rapid morpho-
logic effects are apparent as increased cell 'rounding-up' fol-
lowing trypsinisation, consistent with EGF-induced tyrosine
phosphorylation ofcytoskeletal-associated substrates. Similar
in vitro variations of cell adhesion are seen in tumour cell
lines expressing erbB-2 receptors with different basal activit-
ies. Exposure of EGF-deprived A431 cells to the tyrosine
phosphatase inhibitor sodium orthovanadate (1 mM for 1 h)
does not cause receptor tyrosine phosphorylation, indicating
that phosphatase activation in these cells requires EGF-
induced tyrosine phosphorylation. Since the extracellular
domains of transmembrane tyrosine phosphatases contain
immunoglobulin-like and/or fibronectin-like motifs which
promote cell adhesion when expressed in catalytically inert
mutants (Gebbink et al., J. Biol. Chem., 1993, 268, 16101),
our findings raise the interesting possibility that growth
factor-induced activation of transmembrane phosphatases
may abrogate tumour cell adhesion in vivo.
5.2 Pattern of adhesion molecule expression on bladder
tumour biopsy and tumour cell lines: effectiveness of cytokine
stimulation in upregulation of these molecules
A.M.E. Nouri, R.F. Hussain & R.T.D. Oliver
Department of Medical Oncology, The Royal London Hos-
pital, London El, UK.
The pattern of cell adhesion molecules (CAM) i.e. leukocyte
function associated antigen-3 (LFA-3) and intercellular
adhesion molecule-l (ICAM-1) expression on bladder tumour
biopsies and tumour cell lines was investigated using different
techniques.
The results showed that 15 of the 25 tumour biopsies were
negative for ICAM-1 and amongst the remaining cases, only
one showed strong staining whereas, LFA-3 was expressed
on 21 of 23 tumours tested. The pattern of ICAM-1 expres-
sion on tumour cell lines was very different from tumour
biopsies in that there were many more strongly expressing
tumours. In the case of LFA-3, whilst the results of estab-
lished cell lines were very similar to those of tumour biopsies,
there were no strongly expressing cases among all the seven
primary lines studied, indicating that the in vitro tumour lines
may not always be the true representative of the original
tumour.
The comparison between ICAM-1 and class II antigen
expression on tumour biopsies showed that there were 11 of
18 cases where either both these molecules were expressed
together or were completely absent. In the remaining seven,
there were six cases where only strong class II expression was
observed.
Exposure of established cell lines to cytokines showed that
interferons (IFN) a had no effect on either ICAM-1 or
LFA-3 expression. Similarly, IFNy showed no effect on
LFA-3 molecule. However, it induced ICAM-l on eight of 11
lines investigated, under conditions where IFNa failed to
have any significant activity. The mean ± SD for control
value of eight responder cell lines was 617 ± 406 and follow-
ing IFNa and IFNy stimulation the values were 702 ± 563
(p = 0.022) and 943 ± 471 (p = 0.001) cpm respectively under
conditions where established cell lines treated with these two
cytokines showed a similar increase in the susceptibility to
non-MHC-restricted cytotoxicity. Transfection of b2-m gene
to correct defective class 1 antigen on a cell line had no effect
on class 11 and ICAM-1 expression.
These results indicate that there is a significant minority of
bladder tumours with defective CAM and this could be an
important factor in the overall tumour escape mechanism(s).
5.3 Inhibition of heterotypic cell to cell adhesion by an RGD
containing peptide
R.D. Bliss, J.A. Kirby, D.A. Browell & T.W.J. Lennard
Department of Surgery, University of Newcastle upon Tyne,
UK.
Binding of tumour cells to the vascular endothelium and the
extracellular matrix is essential to the metastatic cascade.
Blockade of this process has been shown to reduce metastases
in vivo and in vitro. Integrins are known to be involved in this
process. Many Integrins bind to an RGD motif which is
common to many of their ligands.
The function of this motif was examined by measuring the
adhesion of MCF-7 cells, a breast tumour cell line, to
EAhy926, an endothelial hybridoma, using varying concentra-
tions of two different peptides.
Confluent monolayers of EAhy926 were grown on 96-well
micro-titre plates and differing concentrations of either the
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labelled with 5'Cr and 3 x 104 cells added to the endothelial
monolayer. After 2 h, non-adherent cells were removed and
the remaining bound cells were lysed. The 5'Cr release was
then measured using a gamma-spectrometer.
This showed that cell-cell adhesion is significantly inhibited
experimentally by use of an RGD-containing peptide, but not
by the tripeptide itself.
Inhibition of adhesion (%)' produced by varying
concentrations ofpeptide
Peptide 0.1 mg/ml JO Lg/ml Iig/ml 0.1lg/ml IOng/ml Ing/ml
RGD 3.3 -16.6 -12.4 -5.4 -2.9 ND
RGDS 25.8** 23.8* 22.9* 17.5 9.6 10.9
'Mean (n = 26); **p<0005; *p<0.05
We conclude that Integrin blockade by an appropriate peptide
can inhibit tumour cell adhesion to vascular endothelium; this
may reduce the incidence of metastases.
5.4 Inhibition of colon cancer cell motlity and attachment to
ECM by interleukin-12
S. Hiscox, M.B. Hallett, M.C.A. Puntis & W.G. Jiang
Department of Surgery, University of Wales College of
Medicine, Cardiff, UK.
Both motility and attachment of tumour cells are regulated by
a number of cytokines, including scatter factor (SF). In this
study we investigated the effects of interleukin 12 (IL-12, also
known as natural killer cell stimulatory factor, NKSF), on the
motility and attachment of human colon cancer cells HRT18
and HT115.
The MTT assay was used to quantify attachment to the
reconstituted basement membrane, Matrigel. The effect on
motility induced by SF (10 ng/ml) was determined by measur-
ing the dissociation of the cells from micro-carrier beads.
Changes in cell-surface E-cadherin were also determined via
indirect immunofluorescence and flow cytometry.
Recombinant human IL-2 (p40) was shown to inhibit
attachment of colon cancer cells to Matrigel (% attach-
ment = 77.0±7.1% for HRT18 and 62.2±5.0% for HT115 in
control; 24.0±9.8% for HRT18 and 9.6±2.4% for HT115
with IL-12 (50 ng/ml)). Scatter factor-induced motility was
decreased by IL-12 as shown by the dissociation assay (results
shown as motility index (mean±sem)).
Control
HRT18
HT115
+SF +SF+IL-12
1.00±0.52 3.26±0.58 1.34±0.32
1.00±0.03 3.00±0.78 1.96±0.33
Interleukin-12 induced effects occurred in a concentration
dependent manner (2-200 ng/ml) and were blocked by an
antibody specific for the IL-12 ligand. Data obtained by flow
cytometry indicated up-regulation of cell-surface E-cadherin.
It is proposed that IL-12 inhibits cell motility and attach-
ment to extracellular matrix proteins via the up-regulation of
the cell-surface E-cadherin.
5.5 Swainsonine directly inhibits invasion of human colorectal
tumour cells in vitro
C. Galustian, S. Foulds & P.J. Guillou
Academic Surgical Unit, St Mary's Hospital Medical School,
London W2 JNY, UK.
Swainsonine (SW), an inhibitor ofglycoprotein processing, has
been shown to inhibit metastasis of murine tumours in vivo.
Previously, we have observed that one mechanism ofthis effect
is an enhancement of anti-tumour immune functions. We now
show that SW also has a direct inhibitory effect on basement
membrane invasion of a human colorectal cell-line, SW620, in
vitro. SW620 cells were incubated with varying SW concentra-
tions for 4 days and then plated onto basement membrane
matrigel coated filters in double chamber cassettes. A 5 h
membrane invasion chamber system (MICS) assay was then
performed. Tumour cells invading from upper to lower
chambers were stained and counted. The results are shown
below as % of control tumour invasion±s.e.
[sWJ](Ag/lml) 0 1 2 5 10
% invasion 100±3.0 48±4.9* 48±5.3* 40±3.0* 38± 2.6*
(p<0.01 by anova compared to control, *=p <0.01 by Duncan's
test).
Mechanisms of this inhibition were then investigated. SW620
tumour cells incubated with 10jug/ml SW for 4 days were
27.5% less adherent to basement membrane matrigel after 1 h
than control cells (p<0.01 by unpaired t-test). SW also in-
creased cell-cell aggregation in SW620 tumour cell cultures:
SW620 cells pre-incubated with 10jig/ml SW had 39%±6.3 of
cell aggregates in the culture compared to 17.32%±5.1 in the
controls (± = s.d., p<0.01 by Mann-Whitney U, n = 7). We
then investigated the effect of SW on the expression of E-
cadherin, a cell-cell adhesion molecule whose loss from cells is
implicated in increased metastatic potential and incubated with
fluorescein labelled anti-E-cadherin antibodies and cell-
expression was increased from 18% in untreated cells to
25%±1.6 (±s.e.d. p<0.001) in cells treated with lOtLg/ml
SW.
In summary, SW directly inhibits basement membrane
invasion of colon tumour cells in vitro, and this effect may be
related to changes in cell-matrix and cell-cell adhesion. These
studies show further evidence of the potential of SW in anti-
metastatic therapy.